EDESA BIOTECH, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $3.50M.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $3.50M, a 458.08% increase year-over-year.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $220.50K.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for fiscal 2025 was $7.72M, a 958.10% increase from fiscal 2024.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for fiscal 2024 was $729.39K.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for fiscal 2021 was $13.75M, a 215.32% increase from fiscal 2020.
- EDESA BIOTECH, INC. stock issued during period, value, new issues for fiscal 2020 was $4.36M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $3.50M 10-Q · filed 2026-08-13 | $7.22M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-14 | $3.72M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.50M 10-Q · filed 2026-02-13 | $10.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $220.50K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $7.72M 10-K · filed 2025-12-12 |
| 2025-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-13 | $7.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $6.87M 10-Q · filed 2026-05-14 | $7.64M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $626.76K 10-Q · filed 2026-02-13 | $1.04M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $729.39K 10-K · filed 2025-12-12 |
| 2024-06-30 | $138.42K 10-Q · filed 2025-08-08 | |
| 2024-03-31 | $275.76K 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $315.20K 10-Q · filed 2025-02-14 | |
| 2021-12-31 | $1.29M 10-Q · filed 2022-02-14 | $14.01M derived: sum of 4 quarters · filed 2022-02-14 |
| 2021-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $13.75M 10-K · filed 2021-12-28 |
| 2021-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-13 | $13.75M derived: sum of 4 quarters · filed 2022-02-14 |
| 2021-03-31 | $12.72M 10-Q · filed 2021-05-14 | $13.75M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-12-31 | $1.03M 10-Q · filed 2022-02-14 | $5.34M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $4.36M 10-K · filed 2021-12-28 |
| 2020-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-13 | |
| 2020-03-31 | $4.32M 10-Q · filed 2021-05-14 | |
| 2018-09-30 | $5.49M 10-K · filed 2018-11-30 | |
| 2016-09-30 | $6.75M 10-K · filed 2017-12-01 | |
| 2014-08-31 | $7.00M 10-K · filed 2016-12-14 | |
| 2013-08-31 | $3.12M 10-K · filed 2015-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |